# Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission

> **NCT05636293** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 62 (actual)

## Conditions studied

- Celiac Disease

## Interventions

- **DRUG:** Ritlecitinib
- **DRUG:** Placebo
- **OTHER:** Gluten

## Key facts

- **NCT ID:** NCT05636293
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-01
- **Primary completion:** 2025-12-09
- **Final completion:** 2026-04-09
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- Pfizer

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05636293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05636293, "Double Blind, Placebo-controlled Trial to Establish Safety and Efficacy of Ritlecitinib in Celiac Disease Patients in Remission". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05636293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*